antibody-therapy
(2)
Star Therapeutics
Star Therapeutics is a South San Francisco clinical-stage biotech building first-in-class antibody medicines for serious diseases, with a 'pipeline-in-a-product' approach. Its lead asset VGA039, developed through subsidiary Vega Therapeutics, is a once-monthly subcutaneous monoclonal antibody targeting Protein S, now in Phase 3 for von Willebrand disease.
Adam Rosenthal
Adam Rosenthal is the CEO and Founder of Star Therapeutics, a clinical-stage biotech he launched in 2018 with a mission to develop life-changing therapies for rare diseases. An MIT and Harvard-trained biomedical engineer, Rosenthal built Star around the insight that shared biology across multiple rare diseases can yield single therapies addressing many conditions at once. His lead asset VGA039 - a first-in-class monoclonal antibody targeting Protein S - entered Phase 3 trials in 2025 for von Willebrand disease, the most common inherited bleeding disorder. Star has raised over $315 million from top-tier life sciences investors including Sanofi Ventures and Viking Global Investors.